Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately bullish: Ten of 12 analysts rate Disc Medicine a buy, with an average “Moderate Buy” recommendation and a 12-month price target of $106.50.
• Insiders have been selling shares: Company insiders sold 153,612 shares worth approximately $11.4 million over the past quarter, while insiders retain a 3.76% ownership stake.
• Disc Medicine shares opened at $82.67, near the upper end of their $40.00–$99.50 one-year range. The company also exceeded quarterly EPS expectations, reporting a loss of $1.54 per share versus the forecasted loss of $1.71.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $106.50.

Several research analysts recently issued reports on IRON shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush reaffirmed an "outperform" rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Wall Street Zen upgraded Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Morgan Stanley reiterated an "overweight" rating and set a $90.00 target price on shares of Disc Medicine in a research report on Monday, August 17th. Finally, HC Wainwright raised their price target on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 34,000 shares of the business's stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $15,871,953.44. The trade was a 13.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the company's stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at approximately $3,663,588.06. This trade represents a 12.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 153,612 shares of company stock valued at $11,431,811 over the last quarter. Company insiders own 3.76% of the company's stock.

Institutional Trading of Disc Medicine

Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming purchased a new position in shares of Disc Medicine in the second quarter valued at $25,000. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine during the 4th quarter valued at about $33,000. Allworth Financial LP purchased a new position in Disc Medicine during the 2nd quarter valued at about $46,000. Nykredit A S purchased a new position in Disc Medicine during the 2nd quarter valued at about $103,000. Finally, Persistent Asset Partners Ltd acquired a new position in Disc Medicine during the fourth quarter worth about $141,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $82.67 on Thursday. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The stock has a market capitalization of $316.63 million, a price-to-earnings ratio of -12.56 and a beta of 1.00. The company has a 50-day simple moving average of $76.56 and a 200-day simple moving average of $69.95. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. On average, analysts predict that Disc Medicine will post -6.61 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source